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Abstract 
Objective 
To describe the incidence, outcome and identify possible risk factors for Post Attenuation 
Neurological Signs (PANS) and seizures in dogs that have undergone attenuation of a 
single congenital portosystemic shunt (CPSS). 
Study Design 
Retrospective cohort study.  
Sample Population 
Dogs (n=253) with a single, congenital portosystemic shunt.  
Methods 
Medical records of dogs with a single CPSS surgically attenuated between February 2000 
and July 2015 were reviewed for signalment, pre and post-operative clinical data, 
including the occurrence of PANS. Univariable and multivariable binary logistic 
regression was used to assess risk factors for PANS and for seizures.  
Results  
Twenty eight (11.1%) dogs developed PANS, including twelve (4.7%) dogs that 
seizured. Five (17.9%) dogs with PANS did not survive to discharge.  
The risk factors for PANS included the presence of HE immediately pre-operatively  
(p=0.038, odds ratio 2.704, confidence interval 1.057-6.922) and increasing age 
(p<0.001, odds ratio 1.476, confidence interval 1.223-1.780). The risk factors for seizures 
included the presence of HE immediately pre-operatively (p=0.048, odds ratio 3.538, 
  
confidence interval 1.013-12.363) and increasing age (p=0.009, odds ratio 1.364, 
confidence interval 1.082-1.720).  
 
Conclusions 
Pre-operative HE and older age in dogs with a CPSS increase the odds of developing 
PANS and seizures. Neither extrahepatic or intrahepatic shunts were at an increased risk 
of developing PANS or seizures. Prophylactic levitiracetam was not protective for the 
development of PANS or seizures.  
 
Clinical Significance 
Our findings would suggest that surgical attenuation of a single CPSS should not be 
excessively delayed and that clinical signs of HE should be stabilized before surgery.  
  
Introduction 
Post Attenuation Neurological Signs (PANS) are a complication of the surgical 
management of Congenital Portosystemic Shunts (CPSS) reported in up to 12% of 
dogs.1–7 Signs vary from mild ataxia 2,8 to generalized seizure activity. 5,6,9 PANS is a 
well recognised complication in dogs, however, the underlying aetiology is unclear and 
may be linked to changes associated with hepatic encephalopathy (HE) prior to surgery. 
6,9  
 
Dogs with CPSS often show signs of HE, a poorly understood syndrome of neurological 
signs caused by alterations of multiple factors including ammonia and false 
neurotransmitters.10–12 In dogs with CPSS, ammonia and inflammatory mediators predict 
the presence of HE13 and indicators of inflammation reduce following successful CPSS 
attenuation.14 HE is commonly observed in people secondary to a variety of liver 
diseases, however the pathogenesis remains unclear.  
 
HE may cause chronic alterations in the central nervous system15–19 and there is direct 
evidence of astrocyte alterations in the brains of dogs with CPSS. 10,21 It is hypothesised 
that the central nervous system becomes adapted to an abnormal metabolic environment 
pre-operatively and a sudden change to this favours an excitatory state.2 Alternatively, 
damage to the CNS as a result of chronic portosystemic shunting, coupled with a 
metabolic event post attenuation could result in PANS.6  
 
  
PANS is recognised to be a separate entity to HE,1 occurring even when the CPSS is fully 
attenuated at surgery.22,23 In one study all animals affected with PANS had normal levels 
of ammonia,24 whereas HE is commonly associated with hyperammonaemia.13  
 
Increasing age has been associated with PANS in some studies 2,6,9, but not others.25,26 
There is conflicting evidence about whether dogs with extrahepatic shunts carry an 
increased risk of developing PANS, and the effect of the method or degree of shunt 
attenuation is unknown.2,4,23,25,27  
 
Changes in sodium affect osmolality. Central pontine myelinolysis is one of the most 
severe causes of post-operative neurological signs in people undergoing orthotopic liver 
transplantation and is associated with rapid correction of hyponatraemia.28 In addition a 
reduction of osmolality is associated with increased risk of seizures in people and other 
animals.19,29  
 
Administration of prophylactic anti-seizure medication to dogs with CPSS in the peri-
operative period has shown mixed results. Peri-operative levetiracetam seemed to reduce 
the incidence of post-operative seizures in one retrospective study,3 whereas 
phenobarbitone potentially reduced the severity, but not the incidence of neurological 
dysfunction in another.2
  
The aim of the current study was to retrospectively review the records of dogs that had 
undergone surgical attenuation of a single CPSS, to describe the incidence, outcome and 
identify risk factors for PANS and seizures. We hypothesised that age, the presence of 
HE pre-surgery, extrahepatic shunt morphology and alterations in osmolality post-
operatively would be significantly associated with the incidence of PANS and seizures. 
Additionally, we hypothesised that peri-operative administration of levetiracetam would 
not affect the incidence of PANS or seizures.  
  
Materials and Methods 
The records of dogs that underwent surgery for the attenuation of a single congenital 
portosystemic shunt at our institution between February 2000 and July 2015 were 
reviewed. Diagnosis of a single CPSS was confirmed at surgery with a mesenteric 
portovenogram in all cases.30 The details recorded were signalment, bodyweight,  
duration of clinical signs related to a CPSS, (neurological, urinary and gastrointestinal), 
severity and duration of HE prior to surgery, response to medical treatment prior to 
surgery, pre-surgery serum albumin, pre and 24hr post-operative plasma ammonia,  peri-
operative levetiracetam, shunt type (intrahepatic or extrahepatic), method of attenuation 
and the degree of attenuation achieved, post-operative serum osmolality at three time 
points, the nature, timing and outcome of any complications related to PANS and the 
number of days hospitalisation. Ammonia was measured using a Stasar III 
Spectrophotometer (Gilford Instrument Laboratories Incorporated, Ohio, USA) or a 
Jenway 6310 Spectrophotometer (Bibby Scientific Limited, Staffordshire, UK). Albumin 
was measured using a ILab 600 clinical chemistry analyser (Instrumentation Labaratory, 
Werfen, Warrington, UK). 
 
Electrolytes, urea (BUN) and glucose were measured using a blood gas analyser.  
Osmolality was calculated by the blood gas analyser using the following formula: 
Osm(mOsm/kg) = 1.86[Na+] + ([Glu]/18) + ([BUN]/2.8) + 9. The same blood gas, 
electrolyte and metabolite analyser was used for individual dogs, but three analysers were 
used over the study period (<2003 IRMA TRUpointR, LifeHealth UK; 2003-2011 Stat 
  
ProfileR Critical Care Xpress, Nova Biomedical UK; >2011 Stat ProfileR pHOxR Ultra, 
Nova Biomedical UK).  
HE before the commencement of medical management (Table 1) and immediately pre-
operatively (Table 2) was graded. Dogs were deemed to have PANS if any neurological 
signs were noted after surgery and before discharge. PANS were graded as mild, 
moderate or severe (Table 3). Dogs underwent CPSS attenuation according to a 
standardized surgical protocol.25,30 The anaesthesia protocol was at the discretion of the 
anaesthetist. As previously reported, the decision to partially or completely attenuate the 
CPSS was made on the basis of portal pressure measured via mesenteric vein 
catheterization and visual assessment of the pancreas and intestinal tract for signs of 
portal hypertension. Dogs that could tolerate a complete attenuation were treated with a 
complete acute suture ligation, those that could not were treated either with a partial 
suture ligation or a cellophane band.30 
 
Statistical analysis was performed using the statistical software package IBM SPSS 
Statistics 23.0.0 (SPSS (UK) Limited IBM, Woking, UK).  Data were assessed 
graphically for normality. Median and range are reported for non-normally distributed 
variables. Categorical data are reported as percentages. The pre-operative and post-
operative levels of plasma ammonia were compared using the Wilcoxon Signed Rank 
Test. Statistical significance was set P ≤ 0.05. 
 
  
Univariable binary logistic regression was performed using each potential predictor 
variable (Tables 5 and 6) as an initial screening to identify possible risk factors for PANS 
and seizures for use in multivariable models.  
 
Variables were selected for univariable binary logistic regression that had been 
previously associated with outcome or were related to the study hypothesis.2,3,6,13,19,31 
Multivariable binary logistic regression models were then developed initially using the 
variables with a P ≤ 0.10 in the univariable analysis. Variables were sequentially entered 
into the logistic regression model and retained if P ≤ 0.05. Once the model was finalized, 
excluded variables were re-assessed by individually re-entering them back into the 
model. Two models were created, one for PANS and one for seizures. 
 
Correlation between variables used in the multivariable analysis was assessed using a 
Spearman’s Rank Correlation.  
  
  
Results 
Two hundred and fifty-three dogs with a single CPSS were included in the study. Three 
other cases were omitted due to incomplete medical records. Where dogs had more than 
one surgery only the details of the first surgery were included. One hundred and thirty-
seven dogs (54.2%) were male and 116 dogs (45.8%) were female. One hundred and 
seventy-five dogs (69.2%) were intact and 78 dogs (30.8%) were neutered. The median 
age at time of surgery was 0.87 years (range 0.20-11.98). The median weight at surgery 
was 6.3kg (range 1.0-50.0). 
 
The median duration of clinical signs prior to surgery was 57 days (range 5-1436). HE 
grade prior to medical management was 1 in 71 dogs (28.1%), 2 in 108 dogs (42.7%), 3 
in 72 dogs (28.5%) and 4 in two dogs (0.8%). Two hundred and thirty-eight dogs (94.1%) 
were treated with medical management prior to surgery and 15 dogs (5.9%) did not 
receive any treatment. Of the 238 dogs that had medical management prior to surgery 
there was a good response in 176 dogs (73.9%), a moderate response in 49 dogs (20.6%) 
and a poor response in 13 (5.5%). The HE grade following medical management was 
grade 1 in 196 dogs (82.4%), grade 2 in 37 dogs (15.5%), grade 3 in four dogs (1.7%) 
and grade 4 in one dog (0.4%). The median duration of medical management prior to 
surgery was 23 days (range 0-730). 
 
One hundred and ninety-six dogs (77.5%) had an extrahepatic CPSS and 57 dogs (22.5%) 
had an intrahepatic CPSS. One hundred and forty-eight dogs (58.5%) were able to 
tolerate a partial attenuation and 105 dogs (41.5%) were able to tolerate a complete 
  
attenuation. Of the 148 dogs treated with a partial attenuation 12 (8.1%) were treated with 
a cellophane band, the remainder with partial suture ligation. 
 
Fifty-four dogs (21.3%) received peri-operative levetiracetam 20mg/kg orally every 8 
hours for a minimum of 24 hours pre-operatively and a minimum of five days post-
operatively. Dogs may have received levetiracetam for longer if prescribed by the 
referring veterinary surgeon.  
 
Serum albumin was measured pre-operatively in 227 dogs (89.7%). The median albumin 
was 26.2g/l (range 7.9-35.8g/l), the reference range 49-71g/l. 
 
Plasma ammonia was measured in 186 dogs (73.5%) pre-operatively. The median 
ammonia concentration was 163.0μmol/l (range 8-590), reference range 0-70μmol/l.  
Post-operative ammonia was measured in 119 dogs with a median of 82μmol/l (range 13-
677). Paired pre and post-operative ammonia samples were available for 104 dogs 
(41.1%). There was a statistically significant decrease in ammonia after surgery from a 
median of 147.5μmol/l (range 8-544) to a median of 80.0μmol/l (range 13-677) 
(p<0.001). 
 
Twelve dogs (4.74%) did not survive to discharge, seven of these dogs died or were 
euthanized for reasons not related to PANS. Three dogs died or were euthanized due to 
severe gastrointestinal haemorrhage, one dog due to suspected portal hypertension and 
pulmonary thromboembolism,  one dog due to severe anaemia secondary to a 
  
coagulopathy, one dog due to a portal vein thrombus and one dog due to postoperative 
intussusception. 
 
Twenty-eight dogs (11.1%) developed PANS (Table 5) with the remaining 225 dogs 
(88.9%) not displaying any post-operative neurological complications. PANS score was 
mild (grade 1) in eleven dogs (39.3%), moderate (grade 2) in four dogs (14.3%) and 
severe (grade 3) in thirteen dogs (46.4%). Twelve dogs (42.9%) suffered post-operative 
generalized seizures (Table 4). Of the 28 dogs that suffered PANS, five (17.9%) did not 
survive to hospital discharge (Table 4). These dogs all suffered seizures meaning that 
5/12 dogs (41.7%) that suffered seizures post-operatively died or were euthanized. None 
of the five dogs that died due to seizures received peri-operative levetiracetam, four out 
of the seven dogs that had seizures but survived to discharge did receive pre-operative 
leviteracetam.  
 
Plasma osmolality was calculated at three time points. The median time interval from 
surgery to first sampling was 1 hour (range 0-4), from surgery to second sample was 8 
hours (range 5-14) and from surgery to third sample was 24 hours (range 14-32). 
Osmolality was calculated at first sampling in 143 dogs with a median of 284.6 (269.6-
316.0). Osmolality was calculated at second sampling in 131 dogs with a median of 282.7 
(263.4-317.0). Osmolality was calculated at third sampling in 131 dogs with a median of 
279.8 (265.5-325.4).  
 
Univariable analysis 
  
 
The results of the univariable binary logistic regression for possible risk factors of PANS 
and seizures are presented in Tables 5 and 6. 
 
Multivariable analysis 
 
The final model of risk factors for PANS included increasing age (p<0.001, Wald 16.561, 
odds ratio [Exp(B)] 1.476, confidence interval 1.223-1.780) and the presence of signs of 
HE immediately pre-operatively (p=0.038, Wald 4.305 odds ratio [Exp(B)] 2.704, 
confidence interval 1.057-6.922).   
 
The final model of risk factors for seizures included increasing age (p=0.009, Wald 
6.904, odds ratio [Exp(B)] 1.364, confidence interval 1.082-1.720) and the presence of 
signs of HE immediately pre-operatively (p=0.048, Wald 3.919 odds ratio [Exp(B)] 
3.538, confidence interval 1.013-12.363).   
 
Increasing age was significantly positively correlated with Osmolality 1 (p<0.001, 
R=0.349), Osmolality 2 (p<0.001, R=0.387), Osmolality 3 (p<0.001, R=0.563) and 
duration of clinical signs (p<0.001, R=0.401) and significantly negatively correlated with 
post-operative ammonia (p=0.005, R=0.255). Duration of clinical signs was significantly 
positively correlated with the duration of medical management (p<0.001, R=0.311). 
  
  
Discussion  
Although PANS do not occur frequently (11.1% in this study) they are a major cause of 
mortality in dogs that have undergone surgical CPSS attenuation. The unknown aetiology 
prevents aimed treatment and symptomatic treatment is centred on the use of anti-seizure 
medication to control neurological signs. Severe PANS may be refractory to such 
measures and this is reflected in a high mortality rate of 20-100%. 2,5–7,24,32,33  
 
PANS may develop due to the triggering of a change in the CNS environment following 
anaesthesia and surgery that has been “set up” by the prior exposure of the astrocytes to 
one or more substances implicated in the pathogenesis of HE.6,9 To our knowledge there 
has not been identification of a risk factor that is predictive for PANS or seizure activity 
following surgical attenuation of a single CPSS. Our aim was to ascertain if clinical, 
biochemical or patient specific risk factors for PANS could be identified. 
 
In this study the presence of HE immediately pre-operatively and age were independent 
risk factors for the development of PANS following surgical attenuation of a single 
CPSS. The odds of PANS occurring in dogs is increased 1.476 times with each year of 
age. The odds of PANS occurring in dogs with signs of HE immediately pre-surgery was 
2.704 times that of those without. 
 
Dogs that are older at the time of surgery have had longer exposure to alterations within 
the CNS. This fits with the suggestion that chronic and/or irreversible astrocyte damage 
by one or more neurotoxic substances is a trigger for the development of neurological 
  
abnormalities when the dog is challenged by an anaesthetic and surgical procedure. This 
is consistent with previous findings suggesting that older dogs are at an increased risk of 
post-operative complications, neurological or otherwise.2,6,7,9,23,34 A previous study 
suggested that age at diagnosis was not associated with long term survival and the authors 
concluded that there was no indication that surgical intervention should be performed 
early in life to be beneficial.35 However, the results of the current study would suggest 
that delaying surgery could increase the risk of PANS. 
 
Dogs that had signs of HE immediately prior to surgery either responded poorly to 
medical therapy or had not received medical therapy. CNS alterations may have been 
more severe, or the lack of medical therapy contributed to an unstable neurological state, 
resulting in a larger relative change in the CNS environment following shunt attenuation. 
The findings of the current study support the notion that alterations in the CNS pre-
operatively are implicated in the neurological dysfunction seen post attenuation. This is 
in agreement with a previous study which indicated that dogs without pre-operative HE 
have fewer complications after CPSS attenuation, compared with dogs with pre-operative 
HE.36 However, they are contrary to the results of another study which concluded that the 
presence of HE pre-operatively did not affect the likelihood of the development of PANS 
or seizure activity.2 Other studies have not been able to draw any conclusions as to the 
significance of pre-operative HE in the development of PANS.3,9 The reasons for 
discrepancies between studies are likely to include sample size, the retrospective nature 
of the studies and the lack of clarification of timing of observation of HE. The 
improvement of HE with medical management makes this information critical.  The 
  
separation of the clinical signs of pre-operative HE and post-operative PANS can be 
difficult, particularly in dogs that have undergone partial shunt attenuation. In this study, 
of the twenty eight dogs with PANS, nine dogs showed clinical signs of HE immediately 
pre-operatively. Paired (pre and post-operative) ammonia samples in three of the dogs 
affected by PANS showed a marked reduction in ammonia, lending evidence to two 
distinct neurological syndromes, and not simply a continuation of HE. 
 
Hyperammonaemia is a common finding in dogs with HE, yet dogs that have undergone 
CPSS attenuation show a decrease in serum ammonia and this has been observed in dogs 
with PANS.13,24,33 The conversion of ammonia to glutamine within the astrocyte is 
considered to be a factor in HE, resulting in osmotic stress and energy depletion.16,37 
However the severity of neurological signs does not always correlate with 
hyperammonaemia and serum levels of ammonia can be normal in dogs, cats and humans 
with HE, suggesting other pathways are also involved. 13,38,39 Pre-operative ammonia 
levels were not associated with the development of PANS in this study, suggesting that 
the pathogenesis of PANS is complex and not related to a sole neurotoxin. 
 
Interestingly, there were several risk factors evaluated in this study that were not found to 
be predictive of PANS. Peri-operative treatment with levetiracetam was instigated at our 
institution in 2012 as result of work by Fryer et al 3 suggesting peri-operative medication 
with levetiracetam reduced the risk of developing seizures post-operatively. However in 
the current study peri-operative levetiracetam did not affect the development of PANS or 
seizure activity which is therefore inconsistent with the aforementioned paper that only 
  
included dogs that developed seizures. Whilst prophylactic levetiracetam did not reduce 
PANS or seizures in this study, it did seem to be associated with reduced mortality in 
severely affected cases. However the cases receiving prophylactic levetiracetam were 
recent and therefore reduced mortality could be explained by increased experience 
treating PANS. It is also important to recognize that although cases receiving 
levetiracetam were treated for at least 24 hours pre-operatively and five days post-
operatively, there may have been variation in the dose and duration of treatment. These 
differences highlight the need for a prospective, controlled study to interrogate the role of 
peri-operative anti-seizure medication for the prevention of PANS.  
 
Neither extrahepatic or intrahepatic shunts were found to be at an increased risk of 
developing PANS or seizure activity in this study. Previously, one study found that dogs 
with extrahepatic shunts were significantly more likely to develop PANS and seizure 
activity compared to intrahepatic shunts.2 Additionally, the degree of attenuation 
achieved was not predictive of neurological dysfunction in the current study.  
 
In the univariable analysis age, the duration of the clinical signs, duration of medical 
management and osmolality at time points 2 and 3 were all significant, but of these, only 
age proved to be a risk factor in the multivariable model. The duration of clinical signs is 
closely related to age and these were significantly correlated. There was also a significant 
correlation between the duration of clinical signs and the duration of medical 
management, which is not surprising. The presence of HE pre-operatively was not 
significant in the univariable analysis but was a risk factor for PANS in the final model.  
  
 
There were also significant correlations between osmolality and age. Osmolality, 
specifically sodium, has been implicated in the pathogenesis of HE in human medicine 
16,29,40 and imbalance is likely to be implicated in HE in dogs, contributing to the 
alzheimer type II changes seen with astrocyte swelling. Interestingly, central pontine 
myelinolysis is associated with rapid correction of hyponatraemia,28 and therefore 
increased osmolality. In the current study osmolality was greater in dogs affected by 
PANS and seizures. The significant differences in osmolality between dogs with and 
without PANS is an interesting finding and worthy of further study. It is possible that the 
changes in post-operative osmolality are directly related to the occurrence of PANS, it is 
also possible that they are result of PANS. Additionally, it is possible that osmolality is 
related to age.  
 
The retrospective nature of this study is limiting, with smaller sub groups for several 
important variables, particularly osmolality. Although analysis of complications and 
behavioural changes used a detailed grading scale, retrospective analysis of these records 
is open to interpretation. Furthermore, information has been collected over an extended 
period. While this allows a large dataset to be analysed it also introduces variability in the 
surgical, anaesthetic and medical management. 
 
Age and the presence of HE immediately pre-operatively were identified as risk factors 
for PANS and seizures in this study, suggesting surgery should not be delayed for a 
prolonged period and emphasizing the need to stabilise clinical signs of HE before 
  
surgery. Further work is necessary to elucidate the underlying mechanism of PANS so 
that strategies can be targeted to prevent or more effectively treat PANS. Although it will 
be difficult to enroll sufficient dogs in a timely manner, a randomised, prospective study 
would be invaluable to confirm if there is any potential benefit of prophylactic anti-
seizure medications in dogs undergoing surgery for a CPSS.  
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Tables 
Table 1: Grading system for hepatic encephalopathy (HE) prior to medical therapy in 
dogs, adapted from Proot et al 41 
HE Grade Clinical signs 
1 Normal, absence of abnormal clinical signs 
2 Lethargy, apathy, minimal disorientation, subtle personality change, 
inappropriate behavior 
3 Hypersalivation, severe ataxia, somnolence but responds to verbal stimuli, 
circling, head pressing 
4 Coma, stupor, repeated seizures.  
 
  
  
Table 2: Grading system for clinical response to pre-operative medical management of 
hepatic encephalopathy (HE) in dogs with a single congenital portosystemic 
shunt(CPSS)30 
 
Grade Clinical signs 
Good No remaining clinical signs 
Moderate Some improvement but clinical signs of HE still present 
Poor Little or no clinical improvement 
 
  
  
Table 3: Grading system for Post Attenuation Neurological Signs (PANS) in dogs 
undergoing surgical management of a single congenital portosystemic shunt (CPSS) 
 
Grade Clinical signs 
1: Mild Subtle depression or behavior change, mild tremors or twitching. Self 
resolves or responds immediately to anti-epileptic drug (AED) 
administration. 
2: Moderate Marked depression or behavior change, whole body tremors or twitching, 
+/- reduced response to visual stimuli. Requires one or more intravenous 
AED and ongoing increases in drugs with regular monitoring/ICU support 
to control PANS. 
3: Severe Progressive, severe depression/coma, nystagmus, complete blindness, 
seizures, requires maximum intervention with two or more AED +/- 
propofol and/or other drugs with continuous monitoring/ICU support. 
 
  
  
Table 4: Details and outcome for 28 dogs affected by Post Attenuation Neurological 
Signs (PANS) following surgical treatment of a single congenital portosystemic shunt 
(CPSS) 
 
 
Case PANS 
grade 
Nature of PANS Pre op 
levetirac
etam 
Survival 
to 
discharge 
1 1 Mild neurological signs for first few hours, resolved without 
treatment. 
No Yes 
2 1 Inappropriate mentation 36 hours post surgery responded 
well to phenobarbitone and diazepam. 
No Yes 
3 1 Prolonged recovery and ataxia, resolved with no treatment. Yes Yes 
4 1 Mild tremor 36 hours post surgery quickly responsive to 
phenobarbitone. 
No Yes 
5 1 Tremors and ataxia immediately post surgery, resolved with 
potassium bromide and levetiracetam. 
No Yes 
6 1 Mild tremors 27 hours post surgery, resolved with no further 
treatment added to preoperative levetiracetam. 
Yes Yes 
7 1 Mild tremors 96 hours post surgery, resolved with addition 
of phenobarbitone to preoperative levetiracetam. 
Yes Yes 
8 1 Paddling forelimbs on recovery, resolved with midazolam. No Yes 
9 1 Mild tremor resolved with no treatment. No Yes 
10 1 Mild tremor 40 hours post surgery, resolved with addition of 
phenobarbitone to preoperative levetiracetam. 
Yes Yes 
11 1 Tremors 24 hours post surgery, resolved with no treatment. No Yes 
12 2 Depression, circling and ataxia, 48 hours post surgery 
resolved with phenobarbitone. 
No Yes 
13 2 Depression, central blindness, head pressing 86 hours post 
surgery, gradual response to phenobarbitone. 
No Yes 
14 2 Depression, visual and proprioceptive deficits 86 hours post 
surgery good response to phenobarbitone. 
No Yes 
15 2 Depression, circling, central blindness 84 hours post surgery 
successful treatment with phenobarbitone. 
No Yes 
16 3 Seizures12 hours post surgery, responded to phenobarbitone. No Yes 
17 3 Seizures 12 hours post surgery good response to 
phenobarbitone, potassium bromide and diazepam. 
No Yes 
18 3 Seizures at 72 hours post surgery. Successfully treated with 
phenobarbitone, levetiracetam and propofol CRI. 
No Yes 
19 3 Seizures activity 6 hours post surgery, improved with 
phenobarbitone. 
No Yes 
20 3 Circling, ataxia, visual deficits and seizure activity 78 hours 
post surgery resolved with addition of phenobarbitone to 
preoperative levetiracetam. 
Yes Yes 
  
21 3 Seizures 28 hours post surgery, resolved with addition of 
phenobarbitone to preoperative levetiracetam. 
Yes Yes 
22 3 Tremors, ataxia and seizures at 52 hours post surgery, 
resolved with the addition of phenobarbitone to preoperative 
levetiracetam. 
Yes Yes 
23 3 Depression, ataxia and central blindness 90 hours post 
surgery, responded to phenobarbitone but still blind at 
discharge. 
Yes Yes 
24 3 Seizures 24 hours post surgery, treated with phenobarbitone 
and propofol continuous rate infusion (CRI). 
No Euthanize
d 
25 3 Seizures 48 hours post surgery, no response to 
phenobarbitone, propofol CRI controlled seizures but unable 
to wean off infusion. 
No Euthanize
d 
26 3 Seizures 48 hours post surgery no response to 
phenobarbitone and diazepam. Propofol CRI controlled 
seizures but unable to wean off infusion. 
No Euthanize
d 
27 3 Seizures 12 hours post surgery, refractory to phenobarbitone 
and propofol CRI. 
No Euthanize
d 
28 3 Seizures 40 hours post surgery, refractory to phenobarbitone 
and levetiracetam. Responded to propofol CRI but developed 
aspiration pneumonia. 
No Euthanize
d 
 
  
  
Table 5: Comparison of clinical variables for dogs with a single congenital 
portosystemic shunt (CPSS) that suffered post attenuation neurological signs (PANS) 
following surgical treatment and those that did not 
 
Variable No PANS – 225 dogs PANS – 28 dogs P value 
Type of shunt Extrahepatic 173 (76.9%) 
Intrahepatic 52 (23.1%) 
Extrahepatic 23 (82.1%) 
Intrahepatic 5 (17.9%) 
0.532 
Degree of attenuation Complete 90 (40.0%) 
Partial 135 (60.0%) 
Complete 15(53.6%) 
Partial 13 (46.4%) 
0.173 
Pre-operative albumin g/l 26.2 (7.9-35.5) 
202 dogs 
26.2 (22.0-35.8) 
25 dogs 
0.154 
Pre-operative ammonia 
μmol/l 
160 (range 8-544)  
163 dogs 
176 (range 36-590) 
23 dogs 
0.434 
Post-operative ammonia 
μmol/l 
86 (range 13-677) 
105 dogs 
56 (range 14-142) 
14 dogs 
0.061 
Age in years 0.79 (0.20-7.80) 
225 dogs 
2.58 (range 0.33-11.98) 
28 dogs 
<0.001 
Hepatic encephalopathy 
(HE) present prior to 
medical management 
No 65 (28.9%) 
Yes 160 (71.1%) 
No 6 (21.4%) 
Yes 22 (78.6%) 
0.410 
Duration of clinical signs 
pre-surgery in days 
56 days (8-1436) 
225 dogs 
103 days (5-1269) 
28 dogs 
0.020 
Duration of medical 
management pre-surgery 
in days 
23 days (range 0-290) 
225 dogs 
21 days (range 0-730) 
28 dogs 
0.037 
Response to medical 
management 
Good 159 (75.4%) 
Moderate / poor 52 
(24.6%) 
Good 17 (63.0%) 
Moderate / poor 10 
(37.0%) 
0.172 
Signs of HE immediately 
pre-operatively 
No 186 (82.7%) 
Yes 39 (17.3%) 
No 19 (67.9%) 
Yes 9 (32.1%) 
0.065 
Prophylactic anti-seizure 
medication 
Yes 48 (21.3%) 
No 177 (78.7%) 
Yes 6 (21.4%) 
No 22 (78.6%) 
0.991 
Osmolality at post-
operative time point 1 
284.5 (269.6-310.4) 
129 dogs 
286.0 (274.2-316.0) 
14 dogs 
0.067 
Osmolality at post-
operative time point 2 
282.4 (263.4-310.4) 
117 dogs 
291.2 (269.1-317.0) 
14 dogs 
0.016 
Osmolality at post-
operative time point 3 
279.8 (265.5-305.5) 
121 dogs 
285.2 (271.7-325.4) 
10 dogs 
0.020 
  
  
Table 6: Comparison of clinical variables for dogs with a single congenital portosystemic 
shunt(CPSS) that suffered seizures following surgical treatment and those that did not. 
Variable No seizures – 241 dogs Seizures – 12 dogs P value 
Type of shunt Extrahepatic 186 (77.2%) 
Intrahepatic 55 (22.8%) 
Extrahepatic 10 (83.3%) 
Intrahepatic 2 (16.7%) 
0.620 
Degree of attenuation Complete 98 (40.7%) 
Partial 143 (59.3%) 
Complete 7 (58.3%) 
Partial 5 (41.7%) 
0.234 
Pre-operative albumin g/l  26.2 (range 7.9-35.8) 
 216 dogs 
 26.2 (range 23.0-31.5) 
11 dogs 
0.450 
Pre-operative ammonia 
μmol/l 
 160.5 (range 8.0-562.0)  
 174 dogs 
 172.0 (range 36.0-590.0) 
12 dogs 
0.816 
Post-operative ammonia 
μmol/l 
85.0 (range 13.0-677.0) 
113 dogs 
52.7 (range 28.0-106.0) 
6 dogs 
0.156 
Age in years 0.8 (range 0.2-12.0) 
 241 dogs 
 2.8 (range 0.8-8.5) 
 12 dogs 
0.006 
Hepatic encepalopathy 
(HE) present prior to 
medical management 
No 68 (28.2%) 
Yes 173 (71.8%) 
No 3 (25.0%) 
Yes 9 (75.0%) 
0.809 
Duration of clinical signs 
presurgery in days 
 55 days (range 5-1436) 
 241 dogs 
195.5 days (range 54-
385) 
12 dogs 
0.162 
Duration of medical 
management pre-surgery 
in days 
24 days (range 4-730) 
226 dogs 
25 days (range 6-181) 
12 dogs 
0.689 
Response to medical 
management 
Good 169 (74.8%) 
Moderate / poor 57 
(25.2%) 
Good 7 (58.3%) 
Moderate / poor 5 
(41.7%) 
0.215 
Signs of HE immediately 
pre-operatively 
No 198 (82.2%) 
Yes 43 (17.8%) 
No 7 (58.3%) 
Yes 5 (41.7%) 
0.051 
Prophylactic anti-seizure 
medication 
Yes 51 (21.2%) 
No 190 (78.9%) 
Yes 3 (25.0%) 
No 9 (75.0%) 
0.752 
Osmolality at post-
operative time point 1 
284.5 (range 269.6-
310.4) 
138 dogs 
295.1 (283.4-316.0) 
5 dogs 
0.001 
Osmolality at post-
operative time point 2 
282.3 (range 263.4-
310.4) 
126 dogs 
298.0 (range 294.1-
317.0) 
5 dogs 
0.002 
Osmolality at post-
operative time point 3 
279.8 (range 265.5-
305.5) 
127 dogs 
293.7 (range 285.1-
325.4) 
4 dogs 
0.006 
 
